The integration of targeted therapies is revolutionizing the management of primary CNS malignancies. Frequently emerging new data can make it challenging to understand the latest systemic therapy recommendations.

The systemic therapy landscape of hepatocellular cancer (HCC) has evolved in recent years as data has become available about the efficacy of immunotherapy in this disease. It can be challenging for health care professionals to keep up with the latest data.

Due to recent FDA approvals, several types of perioperative systemic therapies are now available for the treatment of resectable non-metastatic non-small cell lung cancer.

Management of Richter transformation (RT) with conventional chemotherapy is largely met with poor responses and short survival.

ALL in the pediatric patient demographic has demonstrated a growing improvement in survival rates over the past five decades. However, challenges in management approaches and prognoses persist.

There has been a major shift in the treatment paradigm of advanced CHL within the last several years, with antibody-drug conjugates and immune checkpoint inhibitors becoming an integral part of front-line treatment, allowing for reduction in toxicities such as pulmonary toxicity associated with b